Research News
Women with a genetic mutation linked to a higher cancer risk who are diagnosed with breast cancer or ovarian cancer and receive chemotherapy treatment have the same or better survival rates as women who don’t have a genetic mutation linked to higher risk.
Women diagnosed with breast cancer who exercised before, during, and after chemotherapy were less likely to have chemo brain.
General oncologists have received new specific, practical recommendations on how to offer individualized palliative care to people diagnosed with metastatic breast cancer.
On Dec. 20, 2019, the U.S. Food and Drug Administration approved Enhertu (chemical name: fam-trastuzumab deruxtecan-nxki) to treat people diagnosed with unresectable HER2-positive breast cancer or metastatic HER2-positive breast cancer that has been treated with two or more anti-HER2 therapies.
Compared with doctors’ choice of chemotherapy, Enhertu (chemical name: fam-trastuzumab-deruxtecan-nxki) improved both progression-free survival and overall survival in people diagnosed with previously treated metastatic HER2-low breast cancer.
A new study by the Centers for Disease Control and Prevention echoes the results of other studies: Breast cancer screening rates dropped dramatically at the beginning of the COVID-19 pandemic, especially among women of certain racial and ethnic groups.
When more Black women diagnosed with early-stage, triple-negative breast cancer joined a study on Imfinzi, the results showed the immunotherapy was as effective in Black women as it was in women of other races and ethnicities.
Exercise helped reduce the risk of heart problems in women receiving treatment for breast cancer.
Fezolinetant, an experimental medicine that doesn’t contain hormones, has successfully treated hot flashes.
In women with extremely dense breasts and a high risk of breast cancer, screening with 3D mammograms — rather than 2D digital mammograms — was linked to a lower risk of advanced-stage disease.
Among women who had breast cancer surgery and axillary lymph node dissection, Black and Hispanic women were more likely to develop lymphedema than white women, as were women who received chemotherapy before surgery, rather than after surgery.
In the years following a DCIS (ductal carcinoma in situ) diagnosis, about one in five invasive breast cancers that developed were not related to the original DCIS lesion.
Women ages 55 and older diagnosed with early-stage, estrogen receptor-positive, progesterone receptor-positive, HER2-negative breast cancer that had low levels of Ki67 protein and a very low risk of recurrence were able to safely skip radiation after lumpectomy.
Many Black people diagnosed with metastatic breast cancer never find out about clinical trials from their doctors even though most of them are open to participating in one.
Trodelvy (chemical name: sacituzumab govitecan-hziy) slightly improved progression-free survival in people diagnosed with metastatic hormone receptor-positive, HER2-negative breast cancer previously treated with hormonal therapy, a CDK4/6 inhibitor, and multiple lines of chemotherapy.
During external whole-breast radiation therapy for breast cancer, women with large breasts who lay facedown had fewer skin side effects than women who lay faceup.
Doctors should recommend regular aerobic and resistance exercise for people receiving cancer treatment.
Women with a history of invasive breast cancer had a higher risk of developing high blood pressure and diabetes than women without a history of breast cancer.
Infertility seems to double the risk of breast cancer in men.
Previous chemotherapy treatment, more belly fat, and being less physically fit led to a lower immune response to a typhoid vaccine in women who’d been treated for breast cancer.
Simple at-home strength exercises plus vitamin D and omega-3 supplements seemed to reduce cancer risk in healthy people age 70 and older.
Women were satisfied with their breasts 10 years after either lumpectomy and radiation or mastectomy and reconstruction for early-stage breast cancer. Still, women who had lumpectomy and radiation had better psychosocial and sexual well-being.
On Aug. 5, 2022, the U.S. Food and Drug Administration approved Enhertu to treat unresectable or metastatic HER2-low breast cancer.
Breast cancer death rates decreased among all racial and ethnic groups from 1990 to 2015 in Florida, but Black women were still twice as likely to die from breast cancer as white women.